A Phase 3 interventional study of Aticaprant and Placebo in Depressive Disorder, Major and Anhedonia, sponsored by Janssen Research & Development, LLC. Terminated at 95 sites in 13 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 44th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 in phase 3, and was the 54th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, France and 4 more countries
Ages 18–65
Intra-Cellular Therapies, Inc.
Ages 18–74
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 203 across the 52 interventional studies, 136 across the 7 observational. Of the 53 that completed or were terminated, 26 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
2 of the studies in Depressive Disorder, Major by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aticaprant
Other: Placebo
Aticaprant will be administered orally.
Also known as: JNJ-67953964
Placebo will be administered orally.
Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse
Relapse is defined as any of the following: MADRS total score \>=22 for 2 consecutive assessments separated by 7 (+/-3) days and/or hospitalization or observation for worsening depression, or any clinically relevant event per clinical judgment suggestive of relapse of depressive illness, such as active suicidal ideation with intent or evidence of suicidal behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS), suicide attempt, completed suicide, or hospitalization for suicide prevention. Relapse date is defined by the second MADRS assessment. MADRS is a clinician-rated 10-item scale scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), with higher scores indicating more severe symptoms. C-SSRS is clinician-rated and reports severity and frequency of suicide-related ideation and behavior, categorized as no ideation/behavior (0), suicidal ideation (1 -5), or suicidal behavior (6 -10), with higher scores reflecting greater severity.
Time frame: From date of DB randomization (Day 113) up to first documentation of relapse (up to early termination of study [Day 140])
Adult subjects who had major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) and an inadequate response to an ongoing antidepressant therapy were treated. Study was conducted in 3 phases: Open label (OL) initial treatment phase (IN), OL treatment stabilization (ST) phase and double blind (DB) treatment maintenance (TM) phase.
| Milestone | OL (IN) Phase: Aticaprant 10 mg | OL (ST) Phase: Aticaprant 10 mg | DB Treatment Maintenance Phase: Aticaprant 10 mg |
|---|---|---|---|
| Started | 47 | 0 | 0 |
| Completed | 19 | 0 | 0 |
| Not completed | 28 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 25 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Milestone | OL (IN) Phase: Aticaprant 10 mg | OL (ST) Phase: Aticaprant 10 mg | DB Treatment Maintenance Phase: Aticaprant 10 mg |
|---|---|---|---|
| Started | 0 | 18 | 0 |
| Completed | 0 | 2 | 0 |
| Not completed | 0 | 16 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 14 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Missing disposition information | 0 | 1 | 0 |
| Milestone | OL (IN) Phase: Aticaprant 10 mg | OL (ST) Phase: Aticaprant 10 mg | DB Treatment Maintenance Phase: Aticaprant 10 mg |
|---|---|---|---|
| Started | 0 | 0 | 2 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 2 |
Relapse is defined as any of the following: MADRS total score \>=22 for 2 consecutive assessments separated by 7 (+/-3) days and/or hospitalization or observation for worsening depression, or any clinically relevant event per clinical judgment suggestive of relapse of depressive illness, such as active suicidal ideation with intent or evidence of suicidal behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS), suicide attempt, completed suicide, or hospitalization for suicide prevention. Relapse date is defined by the second MADRS assessment. MADRS is a clinician-rated 10-item scale scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), with higher scores indicating more severe symptoms. C-SSRS is clinician-rated and reports severity and frequency of suicide-related ideation and behavior, categorized as no ideation/behavior (0), suicidal ideation (1 -5), or suicidal behavior (6 -10), with higher scores reflecting greater severity.
| days | DB Treatment Maintenance Phase: Aticaprant 10 mg |
|---|---|
| Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse | NA (NA to NA) |
Collected over OL (IN) Arm: From Day 1 up to Week 8; OL (ST) Arm: From Week 7 up to Week 18; DB (TM) Arm: From Week 16 up to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OL (IN) Phase: Aticaprant 10 mg | 0/47 (0%) | 0/47 (0%) | 13/47 (27.7%) |
| OL (ST) Phase: Aticaprant 10 mg | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| DB Treatment Maintenance Phase: Aticaprant 10 mg | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | OL (IN) Phase: Aticaprant 10 mg | OL (ST) Phase: Aticaprant 10 mg | DB Treatment Maintenance Phase: Aticaprant 10 mg |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 5/47 | 2/18 | 0/2 |
| HeadacheNervous system disorders | 4/47 | 0/18 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 3/47 | 1/18 | 0/2 |
| DyspepsiaGastrointestinal disorders | 3/47 | 0/18 | 0/2 |
| InfluenzaInfections and infestations | 1/47 | 1/18 | 0/2 |
| NasopharyngitisInfections and infestations | 1/47 | 1/18 | 0/2 |
| Procedural PainInjury, poisoning and procedural complications | 0/47 | 1/18 | 0/2 |
| Age, Categorical(Participants) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 47 |
| >=65 years | 0 |
| Age, Continuous(years) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| Mean | 42.5 ± 12.58 |
| Sex: Female, Male(Participants) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| Female | 35 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 25 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 43 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | OL (IN) Phase: Aticaprant 10 mg |
|---|---|
| Argentina | 5 |
| Brazil | 3 |
| Bulgaria | 1 |
| Germany | 4 |
| Mexico | 7 |
| Poland | 10 |
| United States | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2024 to primary completion in Apr 2025, 6 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aticaprant
Janssen Research & Development, LLC →